Invesco Ltd. Has $3.04 Million Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

Invesco Ltd. raised its holdings in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 21.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 203,987 shares of the company's stock after buying an additional 35,905 shares during the quarter. Invesco Ltd. owned 0.22% of Arcus Biosciences worth $3,037,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. R Squared Ltd bought a new stake in Arcus Biosciences in the fourth quarter valued at about $26,000. US Bancorp DE grew its stake in shares of Arcus Biosciences by 2,432.0% in the 4th quarter. US Bancorp DE now owns 6,887 shares of the company's stock valued at $103,000 after purchasing an additional 6,615 shares during the period. AXQ Capital LP acquired a new position in shares of Arcus Biosciences in the 4th quarter worth approximately $160,000. KLP Kapitalforvaltning AS bought a new position in shares of Arcus Biosciences during the 4th quarter worth approximately $207,000. Finally, Teacher Retirement System of Texas boosted its stake in Arcus Biosciences by 19.2% in the 4th quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company's stock valued at $223,000 after buying an additional 2,410 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.

Arcus Biosciences Trading Up 2.0 %

Shares of NYSE RCUS traded up $0.18 during midday trading on Friday, hitting $8.80. The stock had a trading volume of 108,877 shares, compared to its average volume of 807,755. The firm has a market cap of $924.69 million, a P/E ratio of -2.79 and a beta of 1.54. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $18.98. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The company's 50-day simple moving average is $8.60 and its 200 day simple moving average is $12.81.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, topping analysts' consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million. Research analysts anticipate that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $18.00 to $24.00 in a report on Wednesday, February 26th. Bank of America reduced their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 19th. Barclays decreased their price objective on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 23rd. Finally, Morgan Stanley reduced their target price on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Arcus Biosciences presently has a consensus rating of "Buy" and a consensus target price of $28.38.

Insider Buying and Selling

In related news, CEO Terry J. Rosen purchased 19,800 shares of Arcus Biosciences stock in a transaction dated Thursday, February 27th. The shares were acquired at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the transaction, the chief executive officer now directly owns 2,554,160 shares of the company's stock, valued at approximately $26,001,348.80. This trade represents a 0.78 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Yasunori Kaneko acquired 20,000 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was bought at an average price of $10.06 per share, with a total value of $201,200.00. Following the acquisition, the director now directly owns 28,400 shares of the company's stock, valued at $285,704. The trade was a 238.10 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.